New inhaled drug shows promise for cystic fibrosis in early trial
NCT ID NCT03375047
First seen Feb 10, 2026 · Last updated Jun 22, 2026 · Updated 18 times
Summary
This early-stage trial tested a drug called MRT5005, given by inhalation, in 42 adults with cystic fibrosis. The main goal was to check safety and how well the body tolerates it. Researchers also looked at changes in lung function. The study is complete, and results may help develop better treatments for cystic fibrosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Maine Medical Center
Portland, Maine, 04102, United States
-
National Jewish Health
Denver, Colorado, 80206, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
New Orleans Center for Clinical Research
Knoxville, Tennessee, 37920, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Oregon Health and Sciences University
Portland, Oregon, 97239, United States
-
University Hospitals
Cleveland, Ohio, 44106, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of Cincinnati
Cincinnati, Ohio, 45267, United States
-
University of Florida
Gainesville, Florida, 32610, United States
-
University of Indiana
Indianapolis, Indiana, 46202, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Utah
Salt Lake City, Utah, 84132, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MRT5005 (a drug given by inhalation)
What this could lead to
If successful, this could point toward a new inhaled treatment to improve lung function in people with cystic fibrosis.
What could go wrong
This is an early phase 1/2 trial with only 42 participants, so results may not apply to everyone. The drug may not improve symptoms or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.